Company Overview
About Tylenol
Tylenol is a global over-the-counter acetaminophen (paracetamol) pain relief and fever reducer brand — owned by Kenvue (NYSE: KVUE), the consumer health company spun off from Johnson & Johnson in May 2023 at a $41 billion IPO valuation, and subject to a pending $48.7 billion acquisition by Kimberly-Clark announced in November 2025 (expected to close second half 2026) — providing consumers with the world's most widely used analgesic through product lines including Tylenol Extra Strength, Tylenol PM, Tylenol Rapid Release Gels, Tylenol Children's, and Tylenol Arthritis Pain for adults and pediatric pain and fever management. Generating approximately $2 billion in annual retail sales as one of Kenvue's flagship brands alongside Neutrogena, Band-Aid, Listerine, and Zyrtec, Tylenol is the #1 recommended pain reliever by doctors and pharmacists in the United States. Originally marketed by McNeil Laboratories (acquired by J&J in 1959), the brand was approved for OTC sale in 1960.
Business Model & Competitive Advantage
Tylenol's acetaminophen formulation addresses the most common everyday pain and fever management needs across the broadest patient population — including groups who cannot safely take NSAIDs (ibuprofen, naproxen, aspirin): patients with ulcers, gastrointestinal conditions, or kidney disease who cannot tolerate NSAID gastric irritation; patients on blood thinners (anticoagulants) where NSAIDs increase bleeding risk; pregnant women for whom acetaminophen is considered the safest OTC analgesic; and elderly patients where NSAID cardiovascular and renal risks are higher. Tylenol's combination formulations (Tylenol PM with diphenhydramine for nighttime, Tylenol Cold + Flu for multi-symptom relief) extend the brand into adjacent OTC categories — making Tylenol the first-reach OTC choice for households managing pain, fever, cold, and sleep.
Competitive Landscape 2025–2026
In 2025, Tylenol (Kenvue) competes in the OTC analgesic, pain relief, and fever reducer market with Advil (Haleon, ibuprofen, $500M+ US revenue), Aleve (Bayer, naproxen), and store brand acetaminophen (private label, 50%+ acetaminophen unit share) for pharmacist recommendation, retail shelf positioning, and consumer household analgesic purchasing. Kimberly-Clark's pending $48.7 billion acquisition of Kenvue (announced November 2025) will bring Tylenol under the same portfolio as Kleenex, Huggies, Kotex, and Scott — creating a diversified consumer products company competing with Procter & Gamble and Unilever across health, hygiene, and household categories. The 2025 strategy under Kenvue (pre-Kimberly-Clark close) focuses on premium product innovation (Tylenol Precise extended-release), growing the e-commerce direct channel, and defending acetaminophen category leadership against store brand share gains.
The Tylenol Story
Founders
Company Timeline
Major milestones in Tylenol's journey
Leadership Team
Meet the leaders behind Tylenol
Thibaut Mongon
Thibaut Mongon serves as CEO of Kenvue, the parent company of Tylenol. He leads the consumer health company spun off from Johnson & Johnson in 2023.
Open Positions
Reddit Discussions
Key Differentiators
Market Leader
Tylenol is recognized as a market leader in the Healthcare sector, demonstrating strong industry presence and customer trust.
Enterprise Scale
With $41000M in revenue, Tylenol operates at enterprise scale with proven market validation.
Frequently Asked Questions
Not So Random Others
Hermes Robotics
Hermes Robotics is an autonomous mobile robot (AMR) and warehouse automation company developing robots and software for logistics and fulfillment operations in warehouses, distribution centers, and ma
Duckie
Duckie is a San Francisco-based AI customer support platform — backed by Y Combinator (W24) with $500,000 in funding from Y Combinator, Andreessen Horowitz, Greylock, KungHo Fund, Netflix, and 5 addit
Zeffy
Zeffy is a Montreal-based fundraising platform for nonprofit organizations that charges zero platform fees on donations — asking donors to optionally contribute a tip to cover Zeffy's operating costs
Oda Studio
Oda Studio is a United States-based AI-powered interior design platform — backed by Y Combinator (W20) — providing homebuyers, renters, and design enthusiasts with AI tools to discover their personal
Bucket Robotics
Bucket Robotics is an autonomous mobile robot (AMR) company that designs modular, rapidly deployable robots for warehouse automation and industrial material handling. Unlike traditional warehouse auto
Nira Energy
Nira Energy is a Denver-based renewable energy software company providing grid capacity mapping and interconnection analysis tools that help solar, battery storage, and data center developers identify
Compare Tylenol with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Tylenol? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Tylenol Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Tylenol vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →